神経医学市場：BCC Research概説

Summary:

The global market for neurology was valued at $63.0 billion in 2023. The market is expected to grow at a compound annual growth rate (CAGR) of 7.1% to reach approximately $94.8 billion by the end of 2029. The neurology sector is dynamic and offers providers a wealth of opportunities for expansion.

神経学の世界市場は、2023 年に 630 億ドルと評価されました。この市場は、年平均成長率 (CAGR) 7.1% で成長し、2029 年末までに約 948 億ドルに達すると予想されています。神経学分野はダイナミックであり、医療提供者に豊富な拡大の機会を提供します。

The demand for medications to treat neurological diseases like Parkinson’s, multiple sclerosis (MS) and Alzheimer’s is expected to rise as their prevalence increases. Due to the availability of better healthcare infrastructure and the rise in the prevalence of chronic diseases, the market for neurological drugs is anticipated to grow at a rapid pace in unexplored emerging markets, including Asia-pacific countries. Additionally, the growing demand for better healthcare services and large government investments in healthcare infrastructure are driving the rapid development of the healthcare sector in emerging economies.

パーキンソン病、多発性硬化症（MS）、アルツハイマー病などの神経疾患の治療薬の需要は、その罹患率が上昇するにつれて高まると予想されています。より優れた医療インフラが利用可能になり、慢性疾患の罹患率が上昇しているため、神経薬の市場はアジア太平洋諸国を含む未開拓の新興市場で急速に成長すると予想されています。さらに、より優れた医療サービスに対する需要の高まりと医療インフラへの政府の大規模な投資が、新興経済における医療分野の急速な発展を牽引しています。

In 2023, the multiple sclerosis market segment held the largest share among disease indication segments. The market has grown significantly in recent years due to improvements in the creation of more potent treatment alternatives. Pharmaceutical companies are spending large sums of money on R&D in an effort to develop a new treatment that will either improve disease management or slow its progression. New technologies like telemedicine and personalized medicine are also making it simpler for patients to get timely, individualized care. The need for treatment solutions has increased as a result of growing patient numbers and increased awareness of MS. The psychotic segment held the second-highest share and generated $14.3 billion in revenue in 2023. Throughout the forecast period, it is expected to grow at a compound annual growth rate (CAGR) of 9.5%.

The segment pertaining to brain tumor diseases is anticipated to expand at the fastest rate (12.6%). The rising incidence of brain cancer worldwide, improvements in drug delivery to the brain via cell-mediated drug transport and nanotechnology, high healthcare costs, diagnostic technology advances, clinical trials and the creation of predictive markers for drug response are all factors contributing to the growth.

Report Scope

This report includes a market analysis of the therapeutics used to treat neurological conditions. The study outlines the market potential for neurology medications for both now and in the future. It also provides a thorough examination of the market’s drivers, constraints, and pipeline medications, as well as the competitive landscape, laws, epidemiology of neurological disorders, mergers and acquisitions. Market forecasts through 2029 are also covered in the report.

このレポートには、神経疾患の治療に使用される治療薬の市場分析が含まれています。この調査では、現在および将来の神経疾患治療薬の市場の可能性について概説しています。また、市場の推進要因、制約、パイプライン薬、競合状況、法律、神経疾患の疫学、合併および買収についても徹底的に調査しています。レポートでは、2029 年までの市場予測も取り上げています。

The report breaks down neurology market shares according to various disease indications. Parkinson’s disease, Alzheimer’s disease, psychotic disorder, epileptic disorder, autism disorder, multiple sclerosis, brain tumor, and other diseases are the neurological disorders that make up the market segmentation. Therapeutics and regional analysis are covered in each disease segment.

このレポートでは、神経学の市場シェアをさまざまな疾患の兆候ごとに分類しています。パーキンソン病、アルツハイマー病、精神病性障害、てんかん性障害、自閉症性障害、多発性硬化症、脳腫瘍、その他の疾患が、市場区分を構成する神経疾患です。各疾患区分では、治療法と地域分析が取り上げられています。

Anti-Parkinson’s medications are covered in the Parkinson’s disease market. The market is divided into different drug classes such as dopaminergic, enzyme inhibitors, dopamine agonists and other anti-Parkinson’s drugs based on drug class. Anti-Alzheimer medications are part of the Alzheimer’s disease market, which is divided into segments according to respective mechanisms of action. The market is divided into two segments based on drug class: NMDA antagonists and AChE inhibitors. Antipsychotic medications are part of the market for psychotic diseases. The market is divided into different drug classes, including D2 partial agonists, D2/5HT2A antagonists, and D2 antagonists.

Anti-epileptic medications are included in the market for epileptic diseases. The market is divided into three segments based on drug class: first-generation, second-generation and third-generation. Autism spectrum disorder drugs are included in the market. Based on information on labels, the market is divided into drug categories: off-label pharmaceuticals and pharmaceuticals with an ASD label. Brain tumor treatments are included in the market for brain tumors. The market is divided into different types of therapy, such as targeted therapy and chemotherapy.

In order to provide an in-depth understanding of the market, profiles of market participants, competitive landscape, key competitors and respective market share are also part of this report. By geographical region, the market in this report is divided into four regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029.

市場を深く理解するために、市場参加者のプロファイル、競争環境、主要な競合他社、およびそれぞれの市場シェアもこのレポートに含まれています。地理的地域別に見ると、このレポートの市場は北米、ヨーロッパ、アジア太平洋、その他の地域 (RoW) の 4 つの地域に分かれています。市場予測については、2023 年を基準年としてデータが提供され、2024 年から 2029 年までの予測が示されています。

Report Synopsis

Report Includes

– 52 data tables and 59 additional tables

– Analyses of the global market trends for neurology therapeutics, with market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024, and projected CAGRs through 2029

– Estimates of the market size and revenue growth prospects, along with a market share analysis by type of disorder, drug classification, mechanism of action, label information, end user and region

– Facts and figures pertaining to key market dynamics, technology advances, pipeline drugs, regulations, and the impact of macroeconomic factors

– Insights derived from the Porter’s Five Forces model, as well as global supply chain and PESTLE analyses

– Pipeline analysis covering ongoing clinical trials and promising forthcoming neuroscience therapies in late stage

– Discussion of therapeutics used for treatment of neurological disorders, along with coverage of novel pipeline drugs, patent expiries of blockbuster drugs and new drug approvals

– A patent analysis, including key granted and published patents

– Analysis of the industry structure, including companies’ market shares and rankings, strategic alliances, M&A activity and a venture funding outlook

– Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, and the ESG scores and practices of leading companies

– Company profiles of major players within the industry, including F. Hoffmann-La Roche Ltd., Novartis AG, UCB S.A, and Otsuka Holdings Co. Ltd.

Table of Contents

Chapter 1 Executive Summary

Market Outlook

Scope of Report

Market Summary

Chapter 2 Market Overview

Overview

Porter’s Five Forces Analysis

Potential for New Entrants (Low to Moderate)

Bargaining Power of Suppliers (Moderate to High)

Bargaining Power of Buyers (Moderate)

Threat of Substitute Products or Services (Moderate to High)

Industry Rivalry (High)

Medical Coding and Billing Challenges in Neurology

Step Therapy

Medicare Cuts

Coding errors

Use of Modifiers

Documentation

Coverage and Prior Authorization

Compliance and Audits

Reimbursement Rate and Denials

Physician Payment Challenges

Evaluation and Management (E/M) – Bill the Correct Level of Care

Negotiating Contracts

Chapter 3 Market Dynamics

Market Dynamics

Market Drivers

Growing Geriatric Population with Neurological Disorders

Increasing Global Incidence of Neurological Disorders

Government and NGO Initiatives in Creating Awareness

Research Initiatives in Neurology

Market Restraints

Patent Expirations of Branded Drugs and Emergence of Generics

Adverse Side Effects

High Cost of Drug Development

Chapter 4 Emerging Trends and Pipeline Analysis

Emerging Trends

Precision Medicine in Neurological Disorders

Gene Therapy for Neurological Disorders

Neurodegeneration and Stem Cell Therapy

Nanotechnology in Neuroscience

Virtual Reality and Digital Therapeutics

Conclusion

Pipeline Analysis

Chapter 5 Regulatory Landscape

Overview

Cross-Disciplinary Value Story

High-Quality Patient-Reported Outcome Data

Impact of New EU and the U.S. Legislation

Conclusion

Chapter 6 Market Segmentation Analysis

Segmental Breakdown

Market Analysis by Disease Indication

Parkinson’s Disease

Alzheimer’s Disease

Psychotic Disorders

Epileptic Disorder

Autism Spectrum Disorder

Brain Tumor

Multiple Sclerosis

Others

Geographic Breakdown

Market Analysis by Region

North America

Europe

Asia-Pacific

Rest of the World

Chapter 7 Competitive Intelligence

Company Share Analysis of Anti-Parkinson’s Drugs

Company Share Analysis of Alzheimer’s Disease Drugs

Company Share Analysis of Antipsychotic Drugs

Company Share Analysis of Anti-Epileptic Drugs

Company Share Analysis of ASD Therapeutics

Company Share Analysis of Brain Tumor Therapeutics

Company Share Analysis of Multiple Sclerosis Therapeutics

Chapter 8 Appendix

Methodology

Sources

Abbreviations

Company Profiles

ABBVIE INC.

ALPHA COGNITION

BIOGEN

BOEHRINGER INGELHEIM INTERNATIONAL GMBH

BRISTOL-MYERS SQUIBB CO.

EISAI CO. LTD.

• HOFFMANN-LA ROCHE LTD.
• LUNDBECK A/S

LILLY

MERCK & CO. INC.

NOVARTIS AG

OTSUKA HOLDINGS CO. LTD.

SANOFI

TEVA PHARMACEUTICAL INDUSTRIES LTD.

UCB S.A.

List of Tables

Summary Table : Global Neurology Market, by Disease Indication, Through 2029

Table 1 : Navigate New Neurology-related Codes

Table 2 : Adverse Side Effects of Some Neurological Drugs

Table 3 : List of Some Clinical Trial Drugs for Parkinson’s Disease in Phase 3 and 4

Table 4 : List of Some Clinical Trial Drugs for Alzheimer’s Disease in Phase 3 and 4

Table 5 : List of Some Clinical Trial Drugs for Epilepsy Disorder in Phase 3 and 4

Table 6 : List of Some Clinical Trial Drugs for Autism Spectrum Disorders in Phase 3 and 4

Table 7 : List of Some Clinical Trial Drugs for Brain Tumors in Phase 3 and 4

Table 8 : List of Some Clinical Trial Drugs for Multiple Sclerosis in Phase 3 and 4

Table 9 : Global Neurology Market, by Disease Indication, Through 2029

Table 10 : Global Neurology Market for Anti-Parkinson’s Drugs, by Drug Class, Through 2029

Table 11 : Global Neurology Market for Anti-Parkinson’s Drugs, by Region, Through 2029

Table 12 : Global Neurology Market for Alzheimer Drugs, by Mechanism of Action, Through 2029

Table 13 : Global Neurology Market for Alzheimer Drugs, by Region, Through 2029

Table 14 : Global Neurology Market for Antipsychotic Drugs, by Mechanism of Action, Through 2029

Table 15 : Some Novel Antipsychotic Drug Targets and Therapeutic Characteristics

Table 16 : Global Neurology Market for Antipsychotic Drugs, by Region, Through 2029

Table 17 : Global Neurology Market for Anti-Epileptic Drugs, by Drug Class, Through 2029

Table 18 : Global Neurology Market for Anti-Epileptic Drugs, by Region, Through 2029

Table 19 : Global Neurology Market for ASD Therapeutics, by Label Information, Through 2029

Table 20 : Global Neurology Market for ASD Therapeutics, by Region, Through 2029

Table 21 : Global Neurology Market for Brain Tumor Therapeutics, by Therapy Type, Through 2029

Table 22 : Global Neurology Market for Brain Tumor Therapeutics, by Region, Through 2029

Table 23 : FDA Approved DMTs

Table 24 : Global Neurology Market for Multiple Sclerosis Therapeutics, by Region, Through 2029

Table 25 : Global Neurology Market for Other Disease Therapeutics, by Region, Through 2029

Table 26 : Global Neurology Market, by Region, Through 2029

Table 27 : North American Neurology Market, by Disease Indication, Through 2029

Table 28 : North American Neurology Market, by Country, Through 2029

Table 29 : U.S. Neurology Market, by Disease Indication, Through 2029

Table 30 : Canadian Neurology Market, by Disease Indication, Through 2029

Table 31 : Mexican Neurology Market, by Disease Indication, Through 2029

Table 32 : European Neurology Market, by Disease Indication, Through 2029

Table 33 : European Neurology Market, by Country, Through 2029

Table 34 : German Neurology Market, by Disease Indication, Through 2029

Table 35 : U.K. Neurology Market, by Disease Indication, Through 2029

Table 36 : French Neurology Market, by Disease Indication, Through 2029

Table 37 : Spanish Neurology Market, by Disease Indication, Through 2029

Table 38 : Italian Neurology Market, by Disease Indication, Through 2029

Table 39 : Rest of European Neurology Market, by Disease Indication, Through 2029

Table 40 : Asia-Pacific Neurology Market, by Disease Indication, Through 2029

Table 41 : Asia-Pacific Neurology Market, by Country, Through 2029

Table 42 : Chinese Neurology Market, by Disease Indication, Through 2029

Table 43 : Japanese Neurology Market, by Disease Indication, Through 2029

Table 44 : Indian Neurology Market, by Disease Indication, Through 2029

Table 45 : Rest of Asia-Pacific Neurology Market, by Disease Indication, Through 2029

Table 46 : Rest of the World Neurology Market, by Disease Indication, Through 2029

Table 47 : Key Companies in Alzheimer’s Generic Drug Market

Table 48 : Key Companies in Alzheimer’s Branded Drug Market

Table 49 : Global Ranking of Leading Manufacturers of ASD Drugs

Table 50 : Information Sources in this Report

Table 51 : Abbreviations Used in the Global Neurology Market Report

Table 52 : AbbVie Inc.: Company Snapshot

Table 53 : AbbVie Inc.: Financial Performance, FY 2022 and 2023

Table 54 : AbbVie Inc.: Product Portfolio

Table 55 : AbbVie Inc: News/Key Developments, 2023 and 2024

Table 56 : Alpha Cognition: Company Snapshot

Table 57 : Alpha Cognition: Financial Performance, FY 2022 and 2023

Table 58 : Alpha Cognition.: Product Portfolio

Table 59 : Alpha Cognition: News/Key Developments, 2024

Table 60 : Biogen.: Company Snapshot

Table 61 : Biogen: Financial Performance, FY 2022 and 2023

Table 62 : Biogen: Product Portfolio

Table 63 : Biogen: News/Key Developments, 2023 and 2024

Table 64 : Boehringer Ingelheim International GmbH: Company Snapshot

Table 65 : Boehringer Ingelheim International GmbH: Financial Performance, FY 2022 and 2023

Table 66 : Boehringer Ingelheim International GmbH: Product Portfolio

Table 67 : Boehringer Ingelheim International GmbH: News/Key Developments, 2024

Table 68 : Bristol-Myers Squibb Co.: Company Snapshot

Table 69 : Bristol-Myers Squibb Co.: Financial Performance, FY 2022 and 2023

Table 70 : Bristol-Myers Squibb Co.: Product Portfolio

Table 71 : Bristol-Myers Squibb Co.: News/Key Developments, 2023 and 2024

Table 72 : Eisai Co. Ltd.: Company Snapshot

Table 73 : Eisai Co. Ltd..: Financial Performance, FY 2022 and 2023

Table 74 : Eisai Co. Ltd.: Product Portfolio

Table 75 : Eisai Co. Ltd.: News/Recent Developments, 2023 and 2024

Table 76 : F. Hoffmann-La Roche Ltd.: Company Snapshot

Table 77 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2022 and 2023

Table 78 : F. Hoffmann-La Roche Ltd.: Product Portfolio

Table 79 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023

Table 80 : H. Lundbeck A/S: Company Snapshot

Table 81 : H. Lundbeck A/S: Financial Performance, FY 2022 and 2023

Table 82 : H. Lundbeck A/S: Product Portfolio

Table 83 : H. Lundbeck A/S: News/Key Developments, 2021 and 2024

Table 84 : Lilly: Company Snapshot

Table 85 : Lilly: Financial Performance, FY 2022 and 2023

Table 86 : Lilly: Product Portfolio

Table 87 : Lilly: News/Key Developments, 2024

Table 88 : Merck & Co. Inc.: Company Snapshot

Table 89 : Merck & Co. Inc.: Financial Performance, FY 2022 and 2023

Table 90 : Merck & Co. Inc.: Product Portfolio

Table 91 : Merck & Co. Inc.: News/Key Developments, 2023

Table 92 : Novartis AG: Company Snapshot

Table 93 : Novartis AG: Financial Performance, FY 2022 and 2023

Table 94 : Novartis AG: Product Portfolio

Table 95 : Novartis AG: News/Key Developments, 2022 and 2023

Table 96 : Otsuka Holdings Co. Ltd.: Company Snapshot

Table 97 : Otsuka Holdings Co. Ltd.: Financial Performance, FY 2022 and 2023

Table 98 : Otsuka Holdings Co. Ltd.: Product Portfolio

Table 99 : Otsuka Holdings Co. Ltd.: News/Key Developments, 2023 and 2024

Table 100 : Sanofi: Company Snapshot

Table 101 : Sanofi: Financial Performance, FY 2022 and 2023

Table 102 : Sanofi: Product Portfolio

Table 103 : Teva Pharmaceutical Industries Ltd.: Company Snapshot

Table 104 : Teva Pharmaceutical Industries Ltd.: Financial Performance, FY 2022 and 2023

Table 105 : Teva Pharmaceutical Industries Ltd.: Product Portfolio

Table 106 : Teva Pharmaceutical Industries Ltd.: News/Key Developments, 2021-2023

Table 107 : UCB S.A.: Company Snapshot

Table 108 : UCB S.A.: Financial Performance, FY 2022 and 2023

Table 109 : UCB S.A.: Product Portfolio

Table 110 : UCB S.A.: News/Key Developments, 2024

List of Figures

Summary Figure : Global Neurology Market Share, by Disease Indication, 2023

Figure 1 : Porter’s Five Forces Analysis of the Neurology Market

Figure 2 : Market Dynamics of Neurology Market

Figure 3 : Breakdown of People Aging 65 or Older with Alzheimer’s Dementia, 2024

Figure 4 : Global Burden of Conditions Affecting the Nervous System, 2021

Figure 5 : Pipeline Analysis of Some Neurological drugs, by Phases, 2024

Figure 6 : Global Neurology Market Share, by Disease Indication, 2023

Figure 7 : Global Neurology Market Share for Anti-Parkinson’s Drugs, by Drug Class, 2023

Figure 8 : Global Neurology Market Share for Anti-Parkinson’s Drugs, by Region, 2023

Figure 9 : Global Neurology Market Share for Alzheimer Drugs, by Mechanism of Action, 2023

Figure 10 : Global Neurology Market Share for Alzheimer Drugs, by Region, 2023

Figure 11 : Global Neurology Market Share for Antipsychotic Drugs, by Mechanism of Action, 2023

Figure 12 : Global Neurology Market Share for Antipsychotic Drugs, by Region, 2023

Figure 13 : Prevalence of Mental Illnesses in U.S. Adult Populations, 2023

Figure 14 : Global Neurology Market Share for Anti-Epileptic Drugs, by Drug Class, 2023

Figure 15 : Global Neurology Market Share for Anti-Epileptic Drugs, by Region, 2023

Figure 16 : Global Neurology Market Share for ASD Therapeutics, by Label Information, 2023

Figure 17 : Global Neurology Market Share for ASD Therapeutics, by Region, 2023

Figure 18 : Global Market Share of Brain and Central Nervous System Cases, both Sexes, by WHO Region, 2022

Figure 19 : Global Neurology Market Share for Brain Tumor Therapeutics, by Therapy Type, 2023

Figure 20 : Global Neurology Market Share for Brain Tumor Therapeutics, by Region, 2023

Figure 21 : Prevalence of Multiple Sclerosis Cases in Select Countries, 2019

Figure 22 : Global Neurology Market Share for Multiple Sclerosis Therapeutics, by Region, 2023

Figure 23 : Global Neurology Market Share for Other Disease Therapeutics, by Region, 2023

Figure 24 : Global Neurology Market Share, by Region, 2023

Figure 25 : North American Neurology Market, by Disease Indication, 2021–2029

Figure 26 : North American Neurology Market Share, by Country, 2023

Figure 27 : European Neurology Market, by Disease Indication, 2021–2029

Figure 28 : European Neurology Market Share, by Country, 2023

Figure 29 : Asia-Pacific Neurology Market, by Disease Indication, 2021–2029

Figure 30 : Asia-Pacific Neurology Market Share, by Country, 2023

Figure 31 : Rest of the World Neurology Market, by Disease Indication, 2021–2029

Figure 32 : Share of Major Players in Anti-Parkinson’s Drugs Market, 2023

Figure 33 : Share of Major Players in Antipsychotic Drugs Market, 2023

Figure 34 : Share of Major Players in Anti-Epileptic Drugs Market, 2023

Figure 35 : Share of Major Players in Brain Tumor Therapeutics Market, 2023

Figure 36 : Share of Major Players in Multiple Sclerosis Therapeutics Market, 2023

Figure 37 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2023

Figure 38 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2023

Figure 39 : Biogen: Revenue Share, by Business Unit, FY 2023

Figure 40 : Biogen: Revenue Share, by Country/Region, FY 2023

Figure 41 : Boehringer Ingelheim International GmbH: Revenue Share, by Business Unit, FY 2023

Figure 42 : Boehringer Ingelheim International GmbH: Revenue Share, by Region/Country, FY 2023

Figure 43 : Bristol-Myers Squibb Co.: Revenue Shares, by Business Unit, FY 2023

Figure 44 : Bristol-Myers Squibb Co.: Revenue Shares, by Country/Region, FY 2023

Figure 45 : Eisai Co. Ltd.: Revenue Share, by Business Unit, FY 2023

Figure 46 : Eisai Co. Ltd.: Revenue Share, by Region/Country, FY 2023

Figure 47 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2023

Figure 48 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2023

Figure 49 : H. Lundbeck A/S: Revenue Share, by Business Unit, FY 2023

Figure 50 : H. Lundbeck A/S: Revenue Share, by Country/Region, FY 2023

Figure 51 : Lilly: Revenue Share, by Business Unit, FY 2023

Figure 52 : Lilly: Revenue Share, by Country/Region, FY 2023

Figure 53 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2023

Figure 54 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2023

Figure 55 : Novartis AG: Revenue Share, by Business Unit, FY 2023

Figure 56 : Novartis AG: Revenue Share, by Country/Region, FY 2023

Figure 57 : Otsuka Holdings Co. Ltd.: Revenue Share, by Business Unit, FY 2023

Figure 58 : Otsuka Holdings Co. Ltd.: Revenue Share, by Country/Region, FY 2023

Figure 59 : Sanofi: Revenue Share, by Business Unit, FY 2023

Figure 60 : Sanofi: Revenue Share, by Country/Region, FY 2023

Figure 61 : Teva Pharmaceutical Industries Ltd.: Revenue Share, by Country/Region, FY 2023

Figure 62 : UCB S.A.: Revenue Share, by Business Unit, FY 2023

Figure 63 : UCB S.A.: Revenue Share, by Country/Region, FY 2023

BCC Research（BCCリサーチ）はライフサイエンス、センサ、マテリアル、環境、商取引関連市場を中心とした広範な市場調査レポートを出版する米国の調査会社です。

ライセンス別価格表

2024年11月より価格構成が大幅に変更になりました。最新の価格についてはお問合せください。

調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。

新価格表

ライセンスタイプ1

ライセンスタイプ2

ライセンスタイプ3

旧価格表

旧ライセンスタイプ1

旧ライセンスタイプ2

ご購入に関するご案内

価格・納期について

• 価格
• ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
• ライセンス
  • シングルユーザライセンス
    • 1名のみレポートファイルのご利用が可能です。
  • 2-5ライセンス
    • 同一企業内5名までレポートファイルのご利用が可能です。
  • サイトライセンス
    • 同一企業同住所内でレポートファイルのご利用が可能です。
  • エンタープライズライセンス
    • 同一企業内人数無制限でレポートファイルのご利用が可能です。
• 納品形態
  • Eメール
• 納期
  • ご注文後3営業日以内

ご注文方法

• レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。

その他

• 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。

BCC Researchが出版する調査レポートのサンプルページのご依頼、見積り、ご質問など購入前のご相談はいつでもお気軽にご連絡ください。

最新調査レポート

• バイオプラスチックの世界市場と技術 2025-03-07
• 半導体製造調査レビュー　2024年 2025-03-06
• 製造市場レビュー　2024年 2025-03-05
• 計測器とセンサの調査レビュー　2024年 2025-03-05
• 航空宇宙用先端材料の世界市場 2025-03-05

BCC Research  出版レポート一覧